Phaseline

Companies › Biomed Industries

Biomed Industries: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Psychiatry; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Bionetide–Phase 3Rett SyndromeSep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06840496BionetidePhase 3Rett SyndromePsychiatrySep 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Gedeon Richter Cybin IRL Beijing Union Pharmaceutical Factory Newron Pharmaceuticals Samuel Fortin

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.